| [1] |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8):801–810.
|
| [2] |
Fleischmann C, Scherag A, Adhikari NKJ, et al. Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193(3):259–272.
|
| [3] |
The ProCESS Investigators: A randomized trial of protocol-based care for early septic shock[J]. N Engl J Med, 2014, 370(18):1683–1693.
|
| [4] |
The ARISE Investigators and the ANZICS Clinical Trials Group: Goal-directed resuscitation for patients with early septic shock[J]. N Engl J Med, 2014, 371(16):1496–1506.
|
| [5] |
Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock[J]. N Engl J Med, 2015, 372(14):1301–1311.
|
| [6] |
Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus ringer′s acetate in severe sepsis[J]. N Engl J Med, 2012, 367(2):124–134.
|
| [7] |
Asfar P, Meziani F, Hamel J-F, et al. High versus low blood-pressure target in patients with septic shock[J]. N Engl J Med, 2014, 370(17):1583–1593.
|
| [8] |
Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock[J]. N Engl J Med, 2014, 371(15):1381–1391.
|
| [9] |
Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock[J]. N Engl J Med, 2014, 370(15):1412–1421.
|
| [10] |
Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial[J]. Intensive Care Med, 2014, 40(10):1399–1408.
|
| [11] |
Harhay MO, Wagner J, Ratcliffe SJ, et al. Outcomes and statistical power in adult critical care randomized trials[J]. Am J Respir Crit Care Med, 2014, 189(12):1469–1478.
|
| [12] |
Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med, 2001, 345(19):1368–1377.
|
| [13] |
Seok J, Warren S, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases[J]. PNAS, 2013, 110(9):357–3512
|
| [14] |
Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome[J]. N Engl J Med, 2013, 368(23):2159–2168.
|
| [15] |
Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive Care[J]. N Engl J Med, 2012, 367(20):1901–1911.
|
| [16] |
Young P, Bailey M, Beasley R, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit[J]. JAMA, 2015, 314(16):1701–1710.
|
| [17] |
Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (Activated) in adults with septic shock[J]. N Engl J Med, 2012, 366(22):2055–2064.
|
| [18] |
Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index[J]. Journal of Clinical Epidemiology, 2014, 67(6):622–628.
|
| [19] |
Ridgeon EE, Young PJ, Bellomo R, et al. The fragility index in multicenter randomized controlled critical care trials[J]. Critical Care Medicine, 2016, 44(7):1278–1284.
|